Download PDF
Semin Respir Crit Care Med 2003; 24(1): 049-060
DOI: 10.1055/s-2003-37916
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Enterococcus: An Emerging Pathogen in Hospitals

Stephen G. Weber, Howard S. Gold
  • Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Further Information

Publication History

Publication Date:
14 March 2003 (online)

    Permissions and Reprints

ABSTRACT

Enterococci remain an important cause of nosocomial infection, particularly among the critically ill. Nationwide, the incidence of enterococcal infections is rising, with an increasing proportion caused by resistant organisms. The spread of vancomycin-resistant enterococci (VRE) within hospitals has been well studied and helps to explain the proliferation of enterococcal disease. After hospital admission of an individual carrying VRE, persistent colonization contributes to the development of a reservoir of colonized inpatients. VRE is usually spread patient to patient by health care workers caring for colonized individuals. To interrupt this phenomenon, infection control efforts including improved hand hygiene, use of gloves and cover gowns, and antibiotic control measures have been promoted. Prospective data concerning the relative benefit of each intervention are limited, and no consensus has emerged regarding the optimal strategy for limiting the dissemination of VRE. Appropriate treatment of an individual patient infected with VRE depends upon successful interpretation of the antibiotic susceptibility profile of the infecting strain. For the critically ill patient, an aggressive approach to diagnosis and therapy is essential. However, even the newest agents available to treat resistant enterococci are limited because of emerging resistance and toxicity.

KEYWORDS

Enterococcus - VRE - infection control - hospital-acquired - critical care

REFERENCES

  • 1 Staphylococcus aureus resistant to vancomycin: United States, 2002.  Morb Mortal Wkly Rep. 2002;  51 565-567
    PubMedGoogle Scholar
  • 2 ational Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992-June 2001, issued August 2001.  }Am J Infect Control. 2001;  29 404-421
    PubMedGoogle Scholar
  • 3 Linden P K. Treatment options for vancomycin-resistant enterococcal infections.  Drugs . 2002;  62 425-441
    CrossrefPubMedGoogle Scholar
  • 4 Facklam R R, Sahm D A. Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology Washington, DC: American Society of Microbiology 1995: 308-314
    Google Scholar
  • 5 Iwen P C, Kelly D M, Linder J. Change in prevalence and antibiotic resistance of Enterococcus species isolated from blood cultures over an 8-year period.  Antimicrob Agents Chemother . 1997;  41 494-495
    PubMedGoogle Scholar
  • 6 Gold H S. Vancomycin-resistant enterococci: mechanisms and clinical observations.  Clin Infect Dis . 2001;  33 210-219
    CrossrefPubMedGoogle Scholar
  • 7 Murray B E. The life and times of the enterococcus.  Clin Microbiol Rev . 1990;  3 46-65
    PubMedGoogle Scholar
  • 8 Rice L B, Carias L L, Hutton-Thomas R. Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium Antimicrob Agents Chemother .  2001;  45 1480-1486
    PubMedGoogle Scholar
  • 9 Rybkine T, Mainardi J L, Sougakoff W. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance.  J Infect Dis . 1998;  178 159-163
    PubMedGoogle Scholar
  • 10 Hanrahan J, Hoyen C, Rice L B. Geographic distribution of a large mobile element that transfers ampicillin and vancomycin resistance between Enterococcus faecium strains.  Antimicrob Agents Chemother . 2000;  44 1349-1351
    CrossrefPubMedGoogle Scholar
  • 11 Coudron P E, Markowitz S M, Wong E S. Isolation of a beta-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium Antimicrob Agents Chemother .  1992;  36 1125-1126
    PubMedGoogle Scholar
  • 12 Moellering R C. Antimicrobial susceptibility of enterococci: in vitro studies of the action of antibiotics alone or in combination. In: Bisno AL, ed. Treatment of Infective Endocarditis New York: Grune & Stratton 1981: 81-96
    Google Scholar
  • 13 Moellering Jr C R, Weinberg A N. Studies on antibiotic syngerism against enterococci, II: Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci.  J Clin Invest . 1971;  50 2580-2584
    PubMedGoogle Scholar
  • 14 Mederski-Samoraj B D, Murray B E. High-level resistance to gentamicin in clinical isolates of enterococci.  J Infect Dis . 1983;  147 751-757
    PubMedGoogle Scholar
  • 15 Murray B E. Vancomycin-resistant enterococcal infections.  N Engl J Med . 2000;  342 710-721
    CrossrefPubMedGoogle Scholar
  • 16 Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium N Engl J Med .  1988;  319 157-161
    PubMedGoogle Scholar
  • 17 Uttley A H, Collins C H, Naidoo J, George R C. Vancomycin-resistant enterococci.  Lancet . 1988;  1 57-58
    PubMedGoogle Scholar
  • 18 Evers S, Quintiliani Jr R, Courvalin P. Genetics of glycopeptide resistance in enterococci.  Microb Drug Resist . 1996;  2 219-223
    PubMedGoogle Scholar
  • 19 Lai K K, Kelley A L, Melvin Z S. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions.  Infect Control Hosp Epidemiol . 1998;  19 647-652
    PubMedGoogle Scholar
  • 20 Bonilla H F, Zervos M A, Lyons M J. Colonization with vancomycin-resistant Enterococcus faecium: comparison of a long-term-care unit with an acute-care hospital.  Infect Control Hosp Epidemiol . 1997;  18 333-339
    PubMedGoogle Scholar
  • 21 Elizaga M L, Weinstein R A, Hayden M K. Patients in long-term-care facilities: a reservoir for vancomycin-resistant enterococci.  Clin Infect Dis . 2002;  34 441-446
    CrossrefPubMedGoogle Scholar
  • 22 Henning K J, Delencastre H, Eagan J. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection.  Pediatr Infect Dis J . 1996;  15 848-854
    CrossrefPubMedGoogle Scholar
  • 23 Bonten M J, Hayden M K, Nathan C. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci.  Lancet . 1996;  348 1615-1619
    CrossrefPubMedGoogle Scholar
  • 24 Jordens J Z, Bates J, Griffiths D T. Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium J Antimicrob Chemother .  1994;  34 515-528
    PubMedGoogle Scholar
  • 25 Ostrowsky B E, Venkataraman L, D'Agata E M. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period.  Arch Intern Med . 1999;  159 1467-1472
    CrossrefPubMedGoogle Scholar
  • 26 D'Agata E M, Jirjis J, Gouldin C, Tang Y W. Community dissemination of vancomycin-resistant Enterococcus faecium Am J Infect Control .  2001;  29 316-320
    PubMedGoogle Scholar
  • 27 Endtz H P, van den Braak N, van Belkum A. Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in the Netherlands.  J Clin Microbiol . 1997;  35 3026-3031
    PubMedGoogle Scholar
  • 28 van den Bogaard E A, Mertens P, London N H, Stobberingh E E. High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in the Netherlands: is the addition of antibiotics to animal feeds to blame?.  J Antimicrob Chemother . 1997;  40 454-456
    CrossrefPubMedGoogle Scholar
  • 29 Kim W J, Weinstein R A, Hayden M K. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period.  J Infect Dis . 1999;  179 163-171
    CrossrefPubMedGoogle Scholar
  • 30 D'Agata E M, Li H, Gouldin C, Tang Y W. Clinical and molecular characterization of vancomycin-resistant Enterococcus faecium strains during establishment of endemicity.  Clin Infect Dis . 2001;  33 511-516
    CrossrefPubMedGoogle Scholar
  • 31 Montecalvo M A, de Lencastre H, Carraher M. Natural history of colonization with vancomycin-resistant Enterococcus faecium Infect Control Hosp Epidemiol .  1995;  16 680-685
    PubMedGoogle Scholar
  • 32 Baden L R, Thiemke W, Skolnik A. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term-care patients and the significance of "clearance." Clin Infect Dis .  2001;  33 1654-1660
    PubMedGoogle Scholar
  • 33 Bonten M J, Slaughter S, Ambergen A W. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable.  Arch Intern Med . 1998;  158 1127-1132
    PubMedGoogle Scholar
  • 34 Puzniak L A, Mayfield J, Leet T. Acquisition of vancomycin-resistant enterococci during scheduled antimicrobial rotation in an intensive care unit.  Clin Infect Dis . 2001;  33 151-157
    CrossrefPubMedGoogle Scholar
  • 35 D'Agata E M, Gautam S, Green W K. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci.  Clin Infect Dis . 2002;  34 167-172
    CrossrefPubMedGoogle Scholar
  • 36 Donskey C J, Chowdhry T K, Hecker M T. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.  N Engl J Med . 2000;  343 1925-1932
    CrossrefPubMedGoogle Scholar
  • 37 Wong M T, Kauffman C A, Standiford H C. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin.  Clin Infect Dis . 2001;  33 1476-1482
    CrossrefPubMedGoogle Scholar
  • 38 Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci.  Infect Control Hosp Epidemiol . 2002;  23 43-44
    PubMedGoogle Scholar
  • 39 Mondy K E, Shannon W, Mundy L M. Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium Clin Infect Dis .  2001;  33 473-476
    PubMedGoogle Scholar
  • 40 Weinstein M R, Dedier H, Brunton J. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium Clin Infect Dis .  1999;  29 361-366
    PubMedGoogle Scholar
  • 41 Wells C L, Juni B A, Cameron S B. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients.  Clin Infect Dis . 1995;  21 45-50
    PubMedGoogle Scholar
  • 42 D'Agata E M, Green W K, Schulman G. Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition.  Clin Infect Dis . 2001;  32 23-29
    CrossrefPubMedGoogle Scholar
  • 43 Bakir M, Bova J L, Newell K A. Epidemiology and clinical consequences of vancomycin-resistant enterococci in liver transplant patients.  Transplantation . 2001;  72 1032-1037
    PubMedGoogle Scholar
  • 44 Hayden M K. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci.  Clin Infect Dis . 2000;  31 1058-1065
    CrossrefPubMedGoogle Scholar
  • 45 Boyce J M, Opal S M, Chow J W. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance.  J Clin Microbiol . 1994;  32 1148-1153
    PubMedGoogle Scholar
  • 46 Beezhold D W, Slaughter S, Hayden M K. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia.  Clin Infect Dis . 1997;  24 704-706
    PubMedGoogle Scholar
  • 47 Garbutt J M, Littenberg B, Evanoff B A. Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile Infect Control Hosp Epidemiol .  1999;  20 664-670
    PubMedGoogle Scholar
  • 48 Katz K C, Gardam M A, Burt J, Conly J M. A comparison of multifaceted versus Clostridium difficile-focused VRE surveillance strategies in a low-prevalence setting.  Infect Control Hosp Epidemiol . 2001;  22 219-221
    PubMedGoogle Scholar
  • 49 Ray A J, Hoyen C K, Das S M. Undetected vancomycin-resistant Enterococcus stool colonization in a Veterans Affairs hospital using a Clostridium difficile-focused surveillance strategy.  Infect Control Hosp Epidemiol . 2002;  23 474-477
    PubMedGoogle Scholar
  • 50 Trick W E, Temple R S, Chen D. Patient colonization and environmental contamination by vancomycin-resistant enterococci in a rehabilitation facility.  Arch Phys Med Rehabil . 2002;  83 899-902
    CrossrefPubMedGoogle Scholar
  • 51 Ray A J, Hoyen C K, Taub T F, Eckstein E C, Donskey C J. Nosocomial transmission of vancomycin-resistant enterococci from surfaces.  JAMA . 2002;  287 1400-1401
    CrossrefPubMedGoogle Scholar
  • 52 Noskin G A, Stosor V, Cooper I. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces.  Infect Control Hosp Epidemiol . 1995;  16 577-581
    CrossrefPubMedGoogle Scholar
  • 53 Byers K E, Durbin L J, Simonton B M. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium Infect Control Hosp Epidemiol .  1998;  19 261-264
    PubMedGoogle Scholar
  • 54 Perry C, Marshall R, Jones E. Bacterial contamination of uniforms.  J Hosp Infect . 2001;  48 238-241
    CrossrefPubMedGoogle Scholar
  • 55 Zachary K C, Bayne P S, Morrison V J. Contamination of gowns, gloves, and stethoscopes with vancomycin-resistant enterococci.  Infect Control Hosp Epidemiol . 2001;  22 560-564
    PubMedGoogle Scholar
  • 56 Larson E L, Early E, Cloonan P. An organizational climate intervention associated with increased handwashing and decreased nosocomial infections.  Behav Med . 2000;  26 14-22
    CrossrefPubMedGoogle Scholar
  • 57 D'Agata E M, Horn M A, Webb G F. The impact of persistent gastrointestinal colonization on the transmission dynamics of vancomycin-resistant enterococci.  J Infect Dis . 2002;  185 766-773
    CrossrefPubMedGoogle Scholar
  • 58 Sakagami Y, Kajimura K. Bactericidal activities of disinfectants against vancomycin-resistant enterococci.  J Hosp Infect . 2002;  50 140-144
    CrossrefPubMedGoogle Scholar
  • 59 Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).  MMWR Recomm Rep . 1995;  44 1-13
    PubMedGoogle Scholar
  • 60 Tenorio A R, Badri S M, Sahgal N B. Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant enterococcus species by health care workers after patient care.  Clin Infect Dis . 2001;  32 826-829
    CrossrefPubMedGoogle Scholar
  • 61 Slaughter S, Hayden M K, Nathan C. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit.  Ann Intern Med . 1996;  125 448-456
    PubMedGoogle Scholar
  • 62 Puzniak L A, Leet T, Mayfield J. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci.  Clin Infect Dis . 2002;  35 18-25
    CrossrefPubMedGoogle Scholar
  • 63 Srinivasan A, Song X, Ross T. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit.  Infect Control Hosp Epidemiol . 2002;  23 424-428
    PubMedGoogle Scholar
  • 64 Sample M L, Gravel D, Oxley C. An outbreak of vancomycin-resistant enterococci in a hematology-oncology unit: control by patient cohorting and terminal cleaning of the environment.  Infect Control Hosp Epidemiol . 2002;  23 468-470
    PubMedGoogle Scholar
  • 65 MacIntyre C R, Empson M, Boardman C. Risk factors for colonization with vancomycin-resistant enterococci in a Melbourne hospital.  Infect Control Hosp Epidemiol . 2001;  22 624-629
    PubMedGoogle Scholar
  • 66 Tornieporth N G, Roberts R B, John J. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients.  Clin Infect Dis . 1996;  23 767-772
    PubMedGoogle Scholar
  • 67 Carmeli Y, Eliopoulos G M, Samore M H. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant enterococcus.  Emerg Infect Dis . 2002;  8 802-807
    PubMedGoogle Scholar
  • 68 Loeb M, Salama S, Armstrong-Evans M. A case-control study to detect modifiable risk factors for colonization with vancomycin-resistant enterococci.  Infect Control Hosp Epidemiol . 1999;  20 760-763
    PubMedGoogle Scholar
  • 69 Fridkin S K, Edwards J R, Courval J M. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 US adult intensive care units.  Ann Intern Med . 2001;  135 175-183
    PubMedGoogle Scholar
  • 70 Moulin F, Dumontier S, Saulnier P. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients.  Clin Microbiol Infect . 1996;  2 192-201
    PubMedGoogle Scholar
  • 71 Husni R, Hachem R, Hanna H, Raad I. Risk factors for vancomycin-resistant enterococcus (VRE) infection in colonized patients with cancer.  Infect Control Hosp Epidemiol . 2002;  23 102-103
    PubMedGoogle Scholar
  • 72 Harris A D, Samore M H, Lipsitch M. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci,and Escherichia coli Clin Infect Dis .  2002;  34 1558-1563
    PubMedGoogle Scholar
  • 73 Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.  Antimicrob Agents Chemother . 2002;  46 1619-1628
    CrossrefPubMedGoogle Scholar
  • 74 Empey K M, Rapp R P, Evans M E. The effect of an antimicrobial formulary change on hospital resistance patterns.  Pharmacotherapy . 2002;  22 81-87
    CrossrefPubMedGoogle Scholar
  • 75 May A K, Melton S M, McGwin G. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.  Shock . 2000;  14 259-264
    PubMedGoogle Scholar
  • 76 Morgan A S, Brennan P J, Fishman N O. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus Ann Pharmacother .  1997;  31 970-973
    PubMedGoogle Scholar
  • 77 Ostrowsky B E, Trick W E, Sohn A H. Control of vancomycin-resistant Enterococcus in health care facilities in a region.  N Engl J Med . 2001;  344 1427-1433
    CrossrefPubMedGoogle Scholar
  • 78 Siddiqui A H, Harris A D, Hebden J. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide.  Am J Infect Control . 2002;  30 40-43
    CrossrefPubMedGoogle Scholar
  • 79 Austin D J, Bonten M J, Weinstein R A. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs.  Proc Natl Acad Sci . 1999;  96 6908-6913
    CrossrefPubMedGoogle Scholar
  • 80 Garrison R N, Fry D E, Berberich S, Polk Jr C H. Enterococcal bacteremia: clinical implications and determinants of death.  Ann Surg . 1982;  196 43-47
    PubMedGoogle Scholar
  • 81 Hoge C W, Adams J, Buchanan B, Sears S D. Enterococcal bacteremia: to treat or not to treat, a reappraisal.  Rev Infect Dis . 1991;  13 600-605
    PubMedGoogle Scholar
  • 82 Caballero-Granado F J, Becerril B, Cuberos L. Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia.  Clin Infect Dis . 2001;  32 587-594
    CrossrefPubMedGoogle Scholar
  • 83 Linden P K, Pasculle A W, Manez R. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E faecium .  Clin Infect Dis . 1996;  22 663-670
    PubMedGoogle Scholar
  • 84 Suppola J P, Kuikka A, Vaara M, Valtonen V V. Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteraemia.  Scand J Infect Dis . 1998;  30 153-157
    PubMedGoogle Scholar
  • 85 Edmond M B, Ober J F, Dawson J D. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality.  Clin Infect Dis . 1996;  23 1234-1239
    PubMedGoogle Scholar
  • 86 Lodise T P, McKinnon P S, Tam V H, Rybak M J. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center.  Clin Infect Dis . 2002;  34 922-929
    CrossrefPubMedGoogle Scholar
  • 87 Lucas G M, Lechtzin N, Puryear D W. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes.  Clin Infect Dis . 1998;  26 1127-1133
    PubMedGoogle Scholar
  • 88 Garbutt J M, Ventrapragada M, Littenberg B. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia.  Clin Infect Dis . 2000;  30 466-472
    CrossrefPubMedGoogle Scholar
  • 89 Lautenbach E, Bilker W B, Brennan P J. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality.  Infect Control Hosp Epidemiol . 1999;  20 318-323
    PubMedGoogle Scholar
  • 90 Cetinkaya Y, Falk P, Mayhall G C. Vancomycin-resistant enterococci.  Clin Microbiol Rev . 2000;  14 686-707
    PubMedGoogle Scholar
  • 91 Murray B E. Vancomycin-resistant enterococci.  Am J Med . 1997;  102 284-293
    CrossrefPubMedGoogle Scholar
  • 92 Westenfelder G O, Paterson P Y, Reisberg B E. Vancomycin-streptomycin synergism in enterococcal endocarditis.  JAMA . 1973;  223 37-40
    CrossrefPubMedGoogle Scholar
  • 93 Costa Y, Galimand M, Leclercq R. Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium Antimicrob Agents Chemother .  1993;  37 1896-1903
    PubMedGoogle Scholar
  • 94 Tsai S F, Zervos M J, Clewell D B. A new high-level gentamicin resistance gene, aph(2")-Id, in Enterococcus spp.  Antimicrob Agents Chemother . 1998;  42 1229-1232
    PubMedGoogle Scholar
  • 95 Wilson W R, Karchmer A W, Dajani A S. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association.  JAMA . 1995;  274 1706-1713
    CrossrefPubMedGoogle Scholar
  • 96 Chow J W. Aminoglycoside resistance in enterococci.  Clin Infect Dis . 2000;  31 586-589
    CrossrefPubMedGoogle Scholar
  • 97 Lautenbach E, Schuster M G, Bilker W B. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus Clin Infect Dis .  1998;  27 1259-1265
    PubMedGoogle Scholar
  • 98 Hayden M K, Koenig G I, Trenholme G M. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations.  Antimicrob Agents Chemother . 1994;  38 1225-1229
    PubMedGoogle Scholar
  • 99 Caron F, Gold H S, Wennersten C B. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother .  1997;  41 2749-2753
    PubMedGoogle Scholar
  • 100 Linden P K, Moellering Jr C R, Wood C A. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.  Clin Infect Dis . 2001;  33 1816-1823
    CrossrefPubMedGoogle Scholar
  • 101 Goff D A, Sierawski S J. Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections.  Pharmacotherapy . 2002;  22 748-758
    CrossrefPubMedGoogle Scholar
  • 102 Williamson J C, Glazier S S, Peacock Jr E J. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin.  Clin Neurol Neurosurg . 2002;  104 54-56
    CrossrefPubMedGoogle Scholar
  • 103 Summers M, Misenhimer G R, Antony S J. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.  South Med J . 2001;  94 353-355
    PubMedGoogle Scholar
  • 104 Raad I, Hachem R, Hanna H. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.  Antimicrob Agents Chemother . 2001;  45 3202-3204
    CrossrefPubMedGoogle Scholar
  • 105 Verma A, Dhawan A, Philpott-Howard J. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin.  J Antimicrob Chemother . 2001;  47 105-108
    CrossrefPubMedGoogle Scholar
  • 106 Carretto E, Barbarini D, Locatelli F. Vancomycin-resistant Enterococcus faecium infection in three children given allogeneic hematopoietic stem cell transplantation: clinical and microbiologic features.  Haematologica . 2000;  85 1158-1164
    PubMedGoogle Scholar
  • 107 Eliopoulos G M, Wennersten C B. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.  Antimicrob Agents Chemother . 2002;  46 1319-1324
    CrossrefPubMedGoogle Scholar
  • 108 Moellering R C, Linden P K, Reinhardt J. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium <~>Synercid Emergency-Use Study Group.  J Antimicrob Chemother . 1999;  44 251-261
    CrossrefPubMedGoogle Scholar
  • 109 Rubinstein E, Prokocimer P, Talbot G H. Safety and tolerability of quinupristin/dalfopristin: administration guidelines.  J Antimicrob Chemother . 1999;  44 (suppl A) 37-46
    CrossrefPubMedGoogle Scholar
  • 110 Mutnick A H, Biedenbach D J, Turnidge J D. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.  Diagn Microbiol Infect Dis . 2002;  43 65-73
    CrossrefPubMedGoogle Scholar
  • 111 Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections.  Eur J Clin Microbiol Infect Dis . 2002;  21 491-498
    CrossrefPubMedGoogle Scholar
  • 112 Till M, Wixson R L, Pertel P E. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium Clin Infect Dis .  2002;  34 1412-1414
    PubMedGoogle Scholar
  • 113 Steinmetz M P, Vogelbaum M A, De Georgia A M. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature.  Crit Care Med . 2001;  29 2383-2385
    CrossrefPubMedGoogle Scholar
  • 114 Bailey E M, Faber M D, Nafziger D A. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis.  Am J Kidney Dis . 2001;  38 E20
    PubMedGoogle Scholar
  • 115 Babcock H M, Ritchie D J, Christiansen E. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.  Clin Infect Dis . 2001;  32 1373-1375
    CrossrefPubMedGoogle Scholar
  • 116 Stefani S, Mezzatesta M L, Tempera G. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.  Clin Microbiol Infect . 2002;  8 368-372
    CrossrefPubMedGoogle Scholar
  • 117 Fang C T, Chang S C, Chen Y C. In vitro activity of linezolid against clinical gram-positive bacterial isolates from Taiwan: an area with a high prevalence of antibiotic resistance.  Int J Antimicrob Agents . 2001;  18 267-270
    PubMedGoogle Scholar
  • 118 Gonzales R D, Schreckenberger P C, Graham M B. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.  Lancet . 2001;  357 1179
    CrossrefPubMedGoogle Scholar
  • 119 Herrero I A, Issa N C, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium N Engl J Med .  2002;  346 867-869
    PubMedGoogle Scholar
  • 120 Jones R N, Della-Latta P, Lee L V, Biedenbach D J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.  Diagn Microbiol Infect Dis . 2002;  42 137-139
    CrossrefPubMedGoogle Scholar
  • 121 Attassi K, Hershberger E, Alam R. Thrombocytopenia associated with linezolid therapy.  Clin Infect Dis . 2002;  34 695-698
    CrossrefPubMedGoogle Scholar
  • 122 Monson T, Schichman S A, Zent C S. Linezolid-induced pure red blood cell aplasia.  Clin Infect Dis . 2002;  35 E29-31
    CrossrefPubMedGoogle Scholar
  • 123 Waldrep T W, Skiest D J. Linezolid-induced anemia and thrombocytopenia.  Pharmacotherapy . 2002;  22 109-112
    PubMedGoogle Scholar
  • 124 Gerson S L, Kaplan S L, Bruss J B. Hematologic effects of linezolid: summary of clinical experience.  Antimicrob Agents Chemother . 2002;  46 2723-2726
    CrossrefPubMedGoogle Scholar
  • 125 Wise R, Andrews J M, Ashby J P. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint.  J Antimicrob Chemother . 2001;  48 563-567
    CrossrefPubMedGoogle Scholar
  • 126 Schouten M A, Voss A, Hoogkamp-Korstanje J A. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.  Antimicrob Agents Chemother . 1999;  43 2542-2546
    PubMedGoogle Scholar
  • 127 Arthur M, Depardieu F, Reynolds P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.  Antimicrob Agents Chemother . 1999;  43 1875-1880
    PubMedGoogle Scholar
  • 128 Boucher H W, Wennersten C B, Eliopoulos G M. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.  Antimicrob Agents Chemother . 2000;  44 2225-2229
    CrossrefPubMedGoogle Scholar